Short answer
PHIBRO ANIMAL HEALTH CORP (PAHC) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $384M (up 10.3% year over year) with net income of $24M.
Q1 2026 key financials · XBRL
- Revenue
- $384M
- +10.3% YoY · +2.6% QoQ
- Net income
- $24M
- +15.1% YoY · −12.5% QoQ
- Operating margin
- 11.6%
- Gross margin
- 32.8%
- EPS (diluted)
- $0.58
- +13.7% YoY · −13.4% QoQ
Source: XBRL data from the PHIBRO ANIMAL HEALTH CORP (PAHC) Q1 2026 10-Q on SEC EDGAR. USD.
PHIBRO ANIMAL HEALTH CORP Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $383.5M, up 10% YoY from $347.8M
- Gross margin 32.8% vs 30.1% YoY; operating margin 11.6% vs 9.6%
- Best segment Animal Health revenue $291.2M, up 13%; worst Performance Products revenue $18.9M, down 17%
- Adjusted EBITDA $60.8M, up 11%; total margin 15.9% vs 15.8% YoY
- MFA portfolio drove $18.9M incremental sales; Brazil’s 180-day virginiamycin transition period creates regulatory headwind
Risk Factors
- No material changes in risk factors from the Annual Report
- Carried-forward risks remain the company’s most significant disclosed exposures
- No new regulatory, legal, or compliance risk identified this quarter
- No new operational, competitive, market, liquidity, debt, currency, or concentration risk identified
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PHIBRO ANIMAL HEALTH CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.